Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
Part of paid clinical trials in Hartford, Connecticut.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00723255
- Phase
- PHASE2
- Status
- Completed
Conditions
- Recurrent Endometrial Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — BIOLOGICALGiven IV
- temsirolimus — DRUGGiven IV
Study Details
This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving bevacizumab together with temsirolimus may kill more tumor cells.
Key Dates
- First listed
- Jul 28, 2008
- Start date
- Sep 30, 2008
- Status verified
- Jul 2019
- Primary completion
- Jul 15, 2011
- Completion
- Jan 25, 2016
Study Design
- Enrollment
- 53 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (bevacizumab, temsirolimus)Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
Primary Outcome Measure
Tumor Response [ Time Frame: Scans are done while patient is on study therapy every other cycle for the first 6 months; then every 3 cycles thereafter; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease ]
Locations (41)
Find similar trials in Hartford, CT
Related Studies
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial CancerPHASE1 · Recruiting · National Cancer Institute (NCI) · Augusta, Georgia